I

ITF Therapeutics

Develops and commercializes rare-disease therapies

Senior Director - Multiple Teams

Biology & BiotechConfirmed live in the last 24 hours
Full-timeConcord, MA, USA$290k - $320kIn-person

About the Job

Requirements

  • MD, PharmD, or PhD in a relevant scientific, medical, or healthcare discipline.
  • At least 12 years of progressive pharmaceutical or biotechnology experience within Medical Affairs, Clinical Development, or related functions.
  • Demonstrated success leading U.S. Medical Affairs organizations and launch readiness activities for rare disease and/or specialty products.
  • Experience partnering effectively with Global Medical Affairs teams in a matrixed multinational organization.
  • Proven ability to influence global strategy through U.S. market insights, external stakeholder engagement, and evidence generation planning.
  • Strong understanding of evidence generation, publication planning, scientific communications, medical governance, and healthcare decision-making processes.
  • Significant experience engaging key opinion leaders, researchers, advocacy organizations, payers, and healthcare systems.
  • Demonstrated ability to operate strategically while driving execution.

Responsibilities

  • Lead development and execution of integrated U.S. Medical Affairs strategies and tactical plans across pre-launch, launch, and lifecycle stages for the neurometabolic therapeutics portfolio.
  • Serve as the senior U.S. medical leader for target neurometabolic diseases, ensuring strategies support appropriate patient identification, disease knowledge, product knowledge, and improved patient outcomes.
  • Lead U.S. medical launch planning and execution activities for the neurometabolic therapeutics portfolio.
  • Establish launch readiness plans spanning field medical, scientific communications, medical education, insight generation, congress strategy, advisory boards, and stakeholder engagement.
  • Partner with Commercial, Market Access, Regulatory, Patient Advocacy, Global Medical Affairs, and Clinical Development teams to coordinate launch execution.
  • Identify and mitigate launch risks while addressing emerging opportunities and competitive dynamics.
  • Lead U.S. scientific communication and medical education strategies, including congress activities, scientific exchange, educational programs, and content development.
  • Align U.S. communication plans with global publication and evidence dissemination strategies.
  • Review and approve U.S. medical materials and ensure communications address stakeholder educational needs.
  • Drive insight generation and translate stakeholder insights into actionable recommendations for development, launch, and lifecycle strategies.
  • Provide U.S. strategic input into evidence generation priorities, study concepts, real-world evidence initiatives, publication planning, and data dissemination activities.
  • Monitor scientific, clinical, regulatory, policy, and competitive developments to inform decision-making.
  • Build and maintain relationships with key opinion leaders, investigators, healthcare professionals, patient advocacy organizations, professional societies, payers, and other stakeholders.
  • Lead advisory boards and expert consultation initiatives to inform medical strategy and evidence priorities.
  • Represent ITF Therapeutics at scientific, advocacy, and industry forums.
  • Partner with Market Access and Health Economics and Outcomes Research to support generation and communication of evidence demonstrating clinical, economic, and patient-centered value.
  • Support payer-facing medical engagements and patient access objectives.
  • Serve as a strategic partner to Commercial, Clinical Development, Regulatory Affairs, Market Access, Safety, Patient Advocacy, and Global Medical Affairs teams.
  • Provide scientific leadership across key business decisions and strategic initiatives.
  • Act as the primary U.S. partner to the Global Neurometabolic Medical Director, contributing U.S. market insights to disease strategy, product strategy, lifecycle planning, evidence generation, publication priorities, and scientific platform development.
  • Align U.S. and global stakeholders, incorporating U.S. insights into global plans while maintaining scientific integrity and patient focus.
  • Build, lead, and develop a high-performing U.S. Medical Affairs neurometabolic team.
  • Coach and mentor team members, fostering accountability, collaboration, innovation, and scientific excellence.
  • Establish priorities, performance expectations, and development plans to support organizational growth and succession planning.
  • Promote a patient-centered culture that balances scientific rigor with meaningful healthcare impact.

Desired Qualifications

  • Experience in neurometabolic disease or lysosomal storage diseases.
  • Experience supporting product launches and pre-launch Medical Affairs activities.
  • Expertise in neurometabolic disorders, rare diseases, neuroscience, genetics, or related therapeutic areas.
  • Experience with insight generation, customer engagement platforms, and customer relationship management systems.
  • Demonstrated success managing departmental budgets and resource planning.
  • Experience working in a global or matrixed organizational environment.

About the Company

ITF Therapeutics

Develops and commercializes rare-disease therapies

ITF Therapeutics is a division of Italfarmaco S.p.A. focused on developing and commercializing treatments for rare diseases in the U.S., especially Duchenne Muscular Dystrophy (DMD). The company works on early-stage research and clinical development, partnering with patient advocacy groups and clinical leaders to align programs with patient needs. Its lead program is DUVYZAT (givinostat), a histone deacetylase (HDAC) inhibitor aimed at DMD. Revenue comes from bringing these specialized therapies to market. Compared with competitors, ITF Therapeutics emphasizes collaboration with patient groups and clinicians, a pipeline-focused early-development approach, and a specialty in HDAC inhibitors for rare diseases. The company’s goal is to deliver effective treatments for rare-disease patients by advancing promising therapies through development and into commercialization.

Company size
1-10
Company stage
Not listed
Total funding
Not listed
Headquarters
Concord, NH
Founded
2024

Recently Posted Jobs

Explore more opportunities at ITF Therapeutics

See more jobs